What's Happening?
Atossa Therapeutics and Calidi Biotherapeutics are set to appear on the RedChip Small Stocks, Big Money show on Bloomberg TV. The program will air interviews with Eric Poma, CEO of Calidi Biotherapeutics, and Steven Quay, CEO of Atossa Therapeutics, discussing their respective companies' advancements in cancer treatment. Calidi Biotherapeutics is focusing on precision genetic medicine through its RedTail platform, which uses engineered viral therapy to target metastatic tumors. Atossa Therapeutics is advancing its lead clinical candidate, (Z)-endoxifen, aimed at improving breast cancer treatment. Both companies are clients of RedChip Companies, which specializes in investor relations for microcap and small-cap companies.
AD
Why It's Important?
The interviews highlight significant advancements in cancer treatment, which could have a profound impact on the healthcare industry. Calidi Biotherapeutics' approach to genetic medicine and Atossa Therapeutics' focus on breast cancer treatment represent potential breakthroughs in oncology. These developments could lead to improved patient outcomes and offer new solutions for diseases with high unmet medical needs. The exposure on Bloomberg TV provides these companies with a platform to reach a broader audience, potentially attracting investors and partnerships that could accelerate their research and commercialization efforts.
What's Next?
Calidi Biotherapeutics is advancing towards an IND filing in 2026 and is exploring strategic partnerships for global commercialization. Atossa Therapeutics is conducting multiple Phase 2 studies to further validate the efficacy of (Z)-endoxifen. Both companies are expected to continue their clinical research and development programs, aiming to bring their innovative treatments to market. The success of these initiatives could lead to significant advancements in cancer therapy and potentially reshape treatment paradigms.
